We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
67 result(s) found, displaying 51 to 60
-
Australian public assessment report (AusPar)AusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Celltrion Healthcare Australia Pty Ltd - Skin-cleaning wipe, sterile.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Celltrion Healthcare Australia Pty Ltd - Antiseptic swab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REMSIMA infliximab 120 mg solution for injection prefilled syringe in auto-injector pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REMSIMA infliximab 120 mg solution for injection prefilled syringe with safety guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REMSIMA infliximab 120 mg solution for injection prefilled syringe.
-
Prescription medicine decision summaryTGA Decision: Yuflyma (adalimumab) is approved to treat multiple auto-immune conditions.
-
Prescription medicine registrationActive ingredients: adalimumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HERZUMA trastuzumab (rch) 440 mg powder for injection for intravenous infusion vial with diluent.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Regdanvimab